within Pharmacolibrary.Drugs.ATC.A;

model A10BD14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.07,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00125,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination antidiabetic medication containing metformin and repaglinide. Metformin is a biguanide that decreases hepatic glucose production, while repaglinide is a meglitinide that stimulates insulin secretion from the pancreas. This combination is intended for the treatment of type 2 diabetes mellitus to improve glycemic control, and is currently approved in several countries.</p><h4>Pharmacokinetics</h4><p>No clinical pharmacokinetic model describing the combination product metformin and repaglinide (A10BD14) in healthy adults or patients has been published to date. Below are estimated pharmacokinetic parameters based on known models for each drug administered orally.</p><h4>References</h4><ol><li><p>Dornhorst, A (2001). Insulinotropic meglitinide analogues. <i>Lancet (London, England)</i> 358(9294) 1709–1716. DOI:<a href=\"https://doi.org/10.1016/S0140-6736(01)06715-0\">10.1016/S0140-6736(01)06715-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11728565/\">https://pubmed.ncbi.nlm.nih.gov/11728565</a></p></li><li><p>Kirchheiner, J, et al., &amp; Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. <i>Clinical pharmacokinetics</i> 44(12) 1209–1225. DOI:<a href=\"https://doi.org/10.2165/00003088-200544120-00002\">10.2165/00003088-200544120-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16372821/\">https://pubmed.ncbi.nlm.nih.gov/16372821</a></p></li><li><p>Kalliokoski, A, et al., &amp; Niemi, M (2010). SLCO1B1 polymorphism and oral antidiabetic drugs. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 107(4) 775–781. DOI:<a href=\"https://doi.org/10.1111/j.1742-7843.2010.00581.x\">10.1111/j.1742-7843.2010.00581.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20406215/\">https://pubmed.ncbi.nlm.nih.gov/20406215</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD14;
